Eisai Co., Ltd. and Eisai, Inc. have signed a $205 million product acquisition agreement with Ligand Pharmaceuticals in which Eisai will obtain exclusive global rights for Ontak, Targretin capsules, Targretin gel 1% and Panretin gel 0.1%. Also, Eisai, Inc. will offer certain Ligand personnel, employment. The acquisition of the four oncology-related products are part of the company’s strategic business plan to help establish Eisai’s global oncology business. “We belie...